Mobility in Atypical Parkinsonism: a Trial of Physiotherapy

Summary

Patients with atypical parkinsonism often show gait and mobility impairment manifesting in early disease stages.

In order to maintain mobility and physical autonomy as long as possible for these patients, we will examine the effect of two types of physiotherapy in patients with multiple system atrophy (MSA), progressive supranuclear gaze palsy (PSP) and idiopathic Parkinson's disease (IPD).

The study is divided into an ambulant daily in-patient physiotherapy phase, followed by a home-based training phase. At the beginning and the end of the study, the patients daily activity will be recorded for one week using Physical Activity Monitoring (PAM) sensors.

The aim of this double-blind, randomized-controlled study is to determine effective physiotherapy in patients with atypical parkinsonian syndromes in order to maintain mobility for as long as possible.

Conditions

• Multiple System Atrophy, Parkinson Variant (Disorder)
• Parkinson Disease
• Progressive Supranuclear Palsy

Interventions

OTHER

Physiotherapy

Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.

Sponsors & Collaborators

• University of Lausanne Hospitals

  collaborator OTHER

• Medical University Innsbruck

  collaborator OTHER

• University of Luxembourg

  collaborator OTHER

• Friedrich-Alexander-Universität Erlangen-Nürnberg

  collaborator OTHER

• Regional Hospital of Bolzano

  collaborator OTHER

• Ecole Polytechnique Fédérale de Lausanne

  collaborator OTHER

• University Hospital Erlangen

  collaborator OTHER

• Reha Rheinfelden

  collaborator OTHER

• Klinik Lengg, Zurich

  collaborator OTHER

• Victoria Sidoroff

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-02-01

Primary Completion

2025-01-08

Completion

2025-01-08

Countries

• Austria

Study Locations